Internal Medicine, Hematology & Oncology · Fort Smith, AR
NPI
1639359714
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
7301 Rogers Ave
Fort Smith, AR, 72903
Phone (479) 274-6200
Groups this clinician bills Medicare through
Medicare paid, 2024
$153K
2,884 services
Medicare patients, 2024
680
Average age 74
Drug cost, 2024
$5.9M
1,581 prescriptions
Company payments, 2025
$3,585
From 42 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Isam A Abdel-Karim was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 875 times for 402 patients. In total Isam A Abdel-Karim billed 2,884 services in 10 codes, and Medicare paid $153K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-04-18.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 875 | 402 | $11.75 | $10K |
| 99214 Office E&M - Established | Facility | 691 | 362 | $62.83 | $43K |
| 99215 Office E&M - Established | Facility | 444 | 171 | $99.73 | $44K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 264 | 116 | $11.56 | $3,052 |
| 99214 Office E&M - Established | Office | 214 | 111 | $63.97 | $14K |
| 99215 Office E&M - Established | Office | 107 | 34 | $97.88 | $10K |
| 99223 Hospital E&M - Initial | Facility | 100 | 91 | $126.69 | $13K |
| 99205 Office E&M - New | Facility | 68 | 68 | $120.35 | $8,184 |
| 99213 Office E&M - Established | Facility | 59 | 47 | $36.75 | $2,168 |
| 99204 Office E&M - New | Facility | 24 | 24 | $93.13 | $2,235 |
| 99213 Office E&M - Established | Office | 17 | 12 | $37.05 | $630 |
| 99205 Office E&M - New | Office | 13 | 13 | $122.05 | $1,587 |
By year: 2022 $133K for 1,934 services; 2023 $143K for 1,895 services; 2024 $153K for 2,884 services.
Medicare prescription drug claims, 2024
In 2024, the drug Isam A Abdel-Karim prescribed most often to Medicare patients was Anastrozole, with 168 prescriptions and refills. In total Isam A Abdel-Karim wrote 1,581 Medicare prescriptions that cost $5.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 168 | 276 | 54 | $2,241 |
| Ondansetron Odt Ondansetron | 98 | 98 | 64 | $4,281 |
| Tamoxifen Citrate Generic | 87 | 140 | 25 | $1,766 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 83 | 83 | 40 | $1,726 |
| Dexamethasone Generic | 71 | 73 | 38 | $1,176 |
| Prochlorperazine Maleate Generic | 59 | 59 | 35 | $1,678 |
| Letrozole Generic | 58 | 104 | 19 | $1,332 |
| Revlimid Lenalidomide | 57 | 57 | Under 11 | $971K |
| Hydroxyurea Generic | 54 | 97 | 15 | $879 |
| Nplate Romiplostim | 51 | 51 | Under 11 | $84K |
| Acyclovir Generic | 47 | 57 | 12 | $646 |
| Prednisone Generic | 43 | 52 | 20 | $267 |
| Abiraterone Acetate Generic | 35 | 35 | Under 11 | $66K |
| Lenalidomide Generic | 30 | 30 | Under 11 | $501K |
| Xtandi Enzalutamide | 29 | 29 | Under 11 | $395K |
Brand drugs: 423 claims; generic drugs: 1,158 claims; opioid claims: 130.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Isam A Abdel-Karim $3,585 ($3,585 in general payments such as food, travel and fees) from 42 companies. The largest payer was Incyte Corporation with $368.
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation INCY | 6 | $368 |
| Janssen Biotech, Inc. JNJ | 14 | $301 |
| Pfizer Inc. PFE | 19 | $257 |
| Merck Sharp & Dohme LLC MRK | 13 | $245 |
| Regeneron Healthcare Solutions, Inc. REGN | 7 | $220 |
| Novartis Pharmaceuticals Corporation NVS | 17 | $197 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 7 | $168 |
| Daiichi Sankyo Inc. 4568.T | 7 | $160 |
| AstraZeneca Pharmaceuticals LP AZN | 8 | $149 |
| Abbvie Inc. ABBV | 9 | $144 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.